Letter to the editor: Comments on ‘A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation’ by Diekstra, F.P. (Frank) et al.
European Journal of Cancer 138 (2020) 54e56Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.ejcancer.comLetter to the EditorLetter to the editor: Comments on ‘A six-weekly dosing
schedule for pembrolizumab in patients with cancer based
on evaluation using modelling and simulation’Meta H.M. Diekstra a,*, Ruben Malmberg a, Stefan Sleijfer b,
Roelof W.F. van Leeuwen a,ba Department of Clinical Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands
b Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the NetherlandsReceived 23 June 2020; accepted 2 July 2020Dear Editor,
With great interest, we read the research article of
Lala et al. [1]. The authors present a robust population
pharmacokinetic (PPK) model of pembrolizumab with
data from 2993 patients and a thorough data interpre-
tation. This research gives a better insight into the
exposureeeresponse relationship for pembrolizumab,
and they concluded that a dose of 2 mg/kg or a fixed
dose of 200 mg every 3 weeks (Q3W) can be extended to
a dose of 400 mg Q6W based on pharmacokinetic
modelling. Although this study provides clear dosingDOI of original article: https://doi.org/10.1016/j.ejca.2020.02.016.
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0959-8049/ª 2020 Elsevier Ltd. All rights reserved.guidelines, a solid pharmaco-economic analysis was left
underexposed to our surprise. Pharmaco-economic an-
alyses are crucial because, in addition to being effective
and safe, appropriate and cost-effective dosing should
also be a part of our daily clinical practice, aiming for
effective allocation of available resources in oncology
[1,2].
The proven feasibility of a six-weekly fixed dosing
interval suggests that a six-weekly weight-based dosing
strategy must be feasible as well (i.e. 4 mg/kg Q6W with
a 400 mg maximum). In addition, previously it was
shown that weight-based dosing of pembrolizumab is
not only equally effective and safe but also more cost-
effective [3e5].
In the initial studies with pembrolizumab, its benefit
has been demonstrated in which it was administered as a
weight-based dose of 2 mg/kg/dose Q3W. For reasons of
simplification of dosing regimens, this was later adjusted
to a fixed dose of 200 mg Q3W in the summary of
product characteristics. This adjustment was based on a
modelling study by Freshwater et al. showing similar
Table 1
Differences in pembrolizumab dosing methods based on 2019 patient population.
Body weight and dose capping* Fixed dose








55 kg 36 (8,53%) 220 mg / 200 mg 2 400 mg 4
55e82,5 kg 231 (54.74%) 220e330 mg / 300 mg 3 400 mg 4
82,5 kg 155 (36.73%) 330 mg / 400 mg 4 400 mg 4
Total number of used vials (% reduction versus 400 mg fixed) 1385 (18%) 1688
IV Z intravenous.
* Weight-based dosing with 4 mg/kg/dose to a maximum dose of 400 mg (dose cap) and rounding using a 10% margin.
** KEYTRUDA 25 mg/ml concentrate for solution for infusion, 4 ml vial (V2860.57 per vial; Dutch standard drug price) [7].
*** Based on total 2019 pembrolizumab administrations.
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studied [4e6].
In the introduction Lala et al. [1] start with
mentioning that it may be possible to conclude that a
new dose regimen is effective and safe solely based on
pharmacokinetic data because of the continuity of
doseeresponse relationships, which means that infor-
mation on the efficacy of a single dose (regimen) is
relevant for the efficacy of another dose (regimen). In
such cases pharmacokinetic parameters are constant,
and this supports our conviction that a pembrolizumab
dose of 2 mg/kg Q3W can be equated to 4 mg/kg/dose
Q6W with similar exposure distributions based on the
PK model of Lala et al. [1].
Lala et al. [1] examined the predicted efficacy and
safety of 400 mg Q6W by matching the predicted Cavg,
Cmin (efficacy) and Cmax (safety) values with data from
multiple clinical trials in which multiple dosing regimens
were studied (2 mg/kg Q3W, 200 mg Q3W and 10 mg/kg
Q2W). Obviously 4 mg/kg Q6W would result in Cmax
values below 10 mg/kg Q2W, but we expect comparable
Cavg values compared with 2 mg/kg Q3W because the
model predicts no significant differences in Cavg between
200 mg Q3W and 400 mg Q6W. We wonder why Lala
et al. did not study whether the 2 mg/kg Q3W dose can
be converted to 4 mg/kg Q6W, which can be easily
examined by performing an additional run on the same
population to predict the efficacy and safety of 4 mg/kg
Q6W or by making the script of this PPK model avail-
able. We do expect that 4 mg/kg Q6W, even as 400 mg
Q6W, will result in a small percentage of patients
(<1.0%) with transiently lower Cmin.ss values. However,
this period will be shorter than seven days, ensuring
maintained target saturation and sufficient efficacy in
this small group of patients [1].
Therefore, we propose a new six-weekly weight-based
dosing regimen with a doubled weight-based dose of
4 mg/kg and a maximum dose of 400 mg. This could
make six-weekly dosing of pembrolizumab much more
cost-effective. In Table 1 we illustrated the different
dosing methods and their corresponding costs andrequired number of vials. On an annual basis, 4 mg/kg
Q6W dosing has a major impact on drug cost savings
[3,7,8]. In the Erasmus MC the average body weight of
patients treated with pembrolizumab is 76 kg. Adoption
of this regimen in our hospital has resulted in an 18%
reduction in the number of vials used, and this has led to
annual savings of approximately V900,000 euros
without vial sharing. Moreover, application of the vial
sharing method could provide even greater savings (up
to 25% vial reduction annually) by reusing the
remainder of used vials for the preparation of the next
dose of the same drug. Because of the physicochemical
stability of pembrolizumab (at least 7 days at room
temperature) the vial sharing method seems a feasible
option [9].
In our clinical setting we, therefore, customised the
dose to 4 mg/kg Q6W with a maximum of 400 mg (dose
capping) with a dose rounding within a 10% margin.
In this way we provide a safe and effective treatment for
oncology patients with a six-weekly dosing interval and
improved cost-effectiveness.
Dosing based on body weight provides significant
cost savings while maintaining safety and efficacy. For
the future, we expect that our proposed measurements
will become even more vital because pembrolizumab will
probably be registered for more indications. In addition,
although it is unclear from the report of Lala et al.,
hopefully the Q6W schedule can also become applicable
for combination therapies of pembrolizumab with other
anticancer agents. In our opinion, dosing of pem-
brolizumab based on body weight with a capped dose of
400 mg represents a more responsible approach than the
fixed dosing regimen. Mainly because of a continuing
rise in healthcare costs, optimisation of dosing strategies
of expensive drugs such as pembrolizumab becomes
more apparent. The aforementioned method may pro-
vide a tool for more efficient dosing and should lead to
major reduction in healthcare costs.
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